FibroGen to Report Third Quarter 2023 Financial Results
23 oct. 2023 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also...
Sickle Cell Disease Treatment Market to hit USD 7.79 billion by 2032, says Global Market Insights Inc.
10 sept. 2023 18h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Sickle Cell Disease Treatment Market size is expected to be worth USD 7.79 billion by 2032. SCD is a genetic disorder that affects millions...
Global Sickle Cell Anemia Testing & Screening Market Forecast 2023-2030: Agios Pharmaceuticals, Bio-Rad, and Quest Diagnostics Among Key Players in Market
21 août 2023 05h43 HE
|
Research and Markets
Dublin, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The "Global Sickle Cell Anemia Testing & Screening Market by Technology, Age Group, Sector - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and...
Akebia’s Vafseo (vadadustat) Poised to Make Waves for GSK’s Jesduvroq and FibroGen/Astellas’ Evrenzo
20 juil. 2023 15h07 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD) patients....
Global Hematology Analyzer Markets Report 2023: 2020-2023 Data & CAGR Projections Through 2028
21 juin 2023 07h48 HE
|
Research and Markets
Dublin, June 21, 2023 (GLOBE NEWSWIRE) -- The "Hematology Analyzer Market" report has been added to ResearchAndMarkets.com's offering.The global market for hematology analyzers was valued at $3.8...
Nemysis Limited Announces Successful IHAT-Gut Trial
11 févr. 2023 03h00 HE
|
Nemysis ltd
DUBLIN, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Nemysis is pleased to announce the publication of the successful findings from the IHAT-Gut trial in iron-deficient anaemic patients (NCT02941081) in the...
FibroGen Reports Third Quarter 2022 Financial Results
07 nov. 2022 16h01 HE
|
FibroGen, Inc.
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
FibroGen to Participate at Stifel 2022 Healthcare Conference
01 nov. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...
Precipio Launches New 1-Step Technology for all HemeScreen Assays
16 août 2022 11h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s...
FibroGen to Report Second Quarter 2022 Financial Results
25 juil. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...